

Receipt
PATENT

Practitioner's Docket No. MPI00-540OMNIM

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Holtzman, Douglas A., et al.
Application No.: 09/811,088 Group No.: 1646
Filed: March 16, 2001 Examiner: Elizabeth Kemmerer
For: NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC,
DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL

1. Transmitted herewith for this application is/are:
 - a. This Transmittal (2 pages);
 - b. Request for Corrected Filing Receipt (2 pages);
 - c. Copy of marked-up Filing Receipt (3 pages); and
 - d. Return Postcard.

STATUS

2. Applicant is other than a small entity.

RECEIVED
FEB 21 2006
TECH CENTER 1600/2900

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: February 8, 2006

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

PETITION FOR EXTENSION OF TIME

3. The proceedings herein are for a patent application and the provisions of 37 C.F.R. 1.136 apply. Applicant petitions for an extension of time under 37 C.F.R. 1.136 (fees: 37 C.F.R. 1.17(a)(1)-(3)) for a 0 month extension:

Fee: \$0.00

If an additional extension of time is required, please consider this a petition therefor.

FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. 1.16(b)-(d)) has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)		OTHER THAN A SMALL ENTITY
	Claims Remaining After Amendment		Highest No. Previously Paid For		Present Extra	Rate	Addit. Fee
Total	0	Minus	0	=	0	\$50.00	= \$0.00
Indep.	0	Minus	0	=	0	\$200.00	= \$0.00
First Presentation of Multiple Dependent Claims			0			\$360.00	= \$0.00
						Total Addit. Fee	\$0.00

Total additional fee for claims required \$0.00

FEE PAYMENT

5. Charge Account No. 501668 the sum of \$0.00 (which includes the extension fee and the \$0.00 additional fee for claims). \$0.00

FEE DEFICIENCY

6. If any additional extension and/or fee is required, charge Account No. 501668.
If any additional fee for claims is required, charge Account No. 501668.

7. Correspondence Address
Direct all future correspondence to:

Customer Number 30405

OR


Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
Cambridge, MA 02139

February 8, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By

Mario Cloutier
Mario Cloutier
Registration No. 57,225
40 Landsdowne Street
Cambridge, MA 02139
Telephone - (617) 577-3522
Facsimile - (617) 551-8820



Patitioner's Docket No. MPI00-5400MNIM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Holtzman, Douglas A., et al.
Application No.: 09/811,088 Group No.: 1646
Filed: March 16, 2001 Examiner: Elizabeth Kemmerer
For: NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC,
DIAGNOSTIC, PREVENTIVE, THERAPEUTIC AND OTHER USES

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CORRECTED FILING RECEIPT

1. Attached is a copy of the official filing receipt received from the PTO in the above application for which issuance of a corrected filing receipt is respectfully requested.

Note: The PTO will not correct the filing receipt until the application is complete (in other words, the applicant files a response to the notice to file missing parts).

2. There is an error with respect to the following data, which is:

{x} incorrectly entered

[] omitted.

RECEIVED
FEB 21 2006
TECH CENTER 1600/2900

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10*

- ☒ with sufficient postage as first class mail. ☐ as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office. (703) 872-9806

Signature _____

Date: February 8, 2006

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-540OMNIM

Error in

1. ☐ Applicant's name
2. ☐ Applicant's address
3. ☐ Title
4. ☐ Filing Date
5. ☐ Serial Number
6. ☐ Foreign/PCT Application Re:
7. ☒ Other – Priority Data is incomplete

Correct data

- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
7. Priority Data should read as follows:
This application is a CIP of
09,712,726 11/14/2000 ABN
which is a CON of 08/820,364 03/12/1997 ABN.
This application 09/811,088
is a CIP of 09/757,421 01/10/2001 ABN,
which is a CON of 08/843,652 04/16/1997 ABN.
This application 09/811,088
is a CIP of 08/843,651 04/16/1997 ABN.
This application 09/811,088
is a CIP of 09/354,809 07/16/1999 ABN
which is a DIV of 08/938,365 09/26/1997 PAT
5,989,909.

3. If any fee is due with this request, charge Deposit Account No. 501668.

February 8, 2006

MILLENNIUM PHARMACEUTICALS, INC.

By: _____

Mario Cloutier


Registration No. 57,225

40 Landsdowne Street

Cambridge, MA 02139

Telephone – (617) 577-3522

Facsimile – (617) 551-8820




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/811,088	03/16/2001	1646	1110	MP12000-540OMNI(M)	30	35	3

30405
MILLENNIUM PHARMACEUTICALS, INC.
40 Landsdowne Street
CAMBRIDGE, MA 02139



CONFIRMATION NO. 8287

CORRECTED FILING RECEIPT



DC000000017902891

Date Mailed: 01/26/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Douglas A. Holtzman, Jamaica Plain, MA;
David P. Gearing, Victoria, AUSTRALIA;
Yang Pan, Bellevue, WA;

RECEIVED
FEB 21 2006
TECH CENTER 1600/2900

Power of Attorney: The patent practitioners associated with Customer Number 30405.

Domestic Priority data as claimed by applicant

This application is a CIP of 09/712,726 11/14/2000 ABN
which is a CON of 08/820,364 03/12/1997 ABN

This application 09/811,088

is a CIP of 09/757,421 01/10/2001 ABN

and is a CON of 08/843,652 04/16/1997 ABN

which is a CIP of 08/843,651 04/16/1997 ABN

This application 09/811,088

is a CIP of 09/354,809 07/16/1999 ABN

which is a DIV of 08/938,365 09/26/1997 PAT 5,989,909

*which is a CON of 08/843,652 04/16/1997 ABN.
This application 09/811,088 is a CIP of 08/843,651
04/16/1997 ABN.*

Foreign Applications

If Required, Foreign Filing License Granted: 05/01/2001

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US09/811,088**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

NOVEL GENES ENCODING PROTEINS HAVING PROGNOSTIC DIAGNOSTIC PREVENTIVE
THERAPEUTIC AND OTHER USES

Preliminary Class

536

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).